Comparative Pharmacology
Head-to-head clinical analysis: EPITOL versus PARADIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPITOL versus PARADIONE.
EPITOL vs PARADIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbamazepine stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting high-frequency repetitive firing of action potentials and reducing synaptic transmission.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Carbamazepine, immediate-release: initial 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Typical maintenance: 800-1200 mg/day in 2-3 divided doses. Extended-release: initial 200 mg orally twice daily; maintenance 400-600 mg twice daily.
100 mg orally three times daily; maximum 600 mg/day.
None Documented
None Documented
20-40 hours (mean 30 hours); linear kinetics at therapeutic doses; decreased with concomitant enzyme-inducing drugs
12-24 hours (terminal); prolonged in renal impairment
Renal: 70% (as glucuronide conjugates and other metabolites), Fecal: 30% (unchanged and metabolites)
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Category C
Category C
Anticonvulsant
Anticonvulsant